


## Patent Covering Innovative Total Artificial Heart Design Granted to SynCardia



Tucson, AZ, March 11th 2024, SynCardia Systems, LLC., a Picard Medical Company, is thrilled to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent for groundbreaking next generation total artificial heart designs under application “Next Generation Total Artificial Heart”.

The patent describes novel technology aimed at eliminating external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle. This new design represents a significant leap forward towards achieving a fully implantable system.

“This achievement is yet another example of SynCardia’s culture of innovation and our commitment to creating state of the art technology to benefit heart failure patients who need a transplant in the US, Europe, Asia, and elsewhere. I am incredibly proud of the hard work and creativity of this team, and I want to congratulate Matt Schuster, our COO and the inventor of this technology”, commented Patrick NJ Schnegelsberg, CEO.

SynCardia Systems, LLC. is a leader in the development of total artificial hearts. The Company markets and sells the SynCardia Total Artificial Heart, which is the only US Food and Drug Administration (FDA) and Health Canada approved artificial heart. As of last year, the Company has implanted 2,080 SynCardia Total Artificial Hearts, including over 100 of the 50cc SynCardia Total Artificial Heart designed for smaller patients.

“This patent represents one of multiple technologies we are pursuing aimed at improving the lives of heart failure patients needing a transplant and we look forward to many more innovations to come,” commented Matt Schuster, COO, and inventor of the technology.

### About SynCardia Systems, LLC

Headquartered in Tucson, Ariz., SynCardia manufactures the world’s only commercially approved total artificial heart. In clinical use for more than 35 years and with more than 2,080 implants, the SynCardia Total Artificial Heart is the most widely used and extensively studied TAH in the world.

By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn’t an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure).

### SynCardia Systems, LLC – a Picard Medical Company

The SynCardia Total Artificial Heart is a treatment option for cardiac transplant-eligible patients at risk of imminent death from biventricular failure.

#### Medical Advice Disclaimer

The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read on this website. © SynCardia Systems, LLC | All rights reserved.



### SynCardia Systems, LLC

1992 E. Silverlake Rd. Tucson, AZ 85713  
+1 520-545-1234 | info@syncardia.com

[www.SynCardia.com](http://www.SynCardia.com)



#SynCardia